¼¼°èÀÇ ¸àÅ×·çÄ«½ºÆ®³ªÆ®·ý ½ÃÀå
Montelukast Sodium
»óǰÄÚµå : 1787177
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 278 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,233,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,701,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¸àÅ×·çÄ«½ºÆ®³ªÆ®·ý ½ÃÀåÀº 2030³â±îÁö 11¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 5¾ï 470¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ¸àÅ×·çÄ«½ºÆ®³ªÆ®·ý ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 14.1%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 11¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Á¤Á¦ ÇüÅ´ CAGR 12.5%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 6¾ï 1,550¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °æ±¸Á¦ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 16.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 1¾ï 3,750¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR18.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¸àÅ×·çÄ«½ºÆ®³ªÆ®·ý ½ÃÀåÀº 2024³â¿¡ 1¾ï 3,750¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR18.6%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿©, 2030³â±îÁö 2¾ï 3,580¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 10.6%¿Í 12.5%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 11.2%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°è ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ýÀÌ È£Èí±â Áúȯ Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ýÀº õ½Ä, ¾Ë·¹¸£±â¼º ºñ¿°, ¿îµ¿ À¯¹ß¼º ±â°üÁö ¼öÃà µî È£Èí±â ÁúȯÀÇ Ä¡·áÁ¦·Î ³Î¸® ó¹æµÇ°í ÀÖ½À´Ï´Ù. ·ùÄÚÆ®¸®¿£ ¼ö¿ëü ±æÇ×Á¦(LTRA)ÀÎ ¸óÅ×·çÄ«½ºÆ®´Â ±âµµ ¼öÃàÀÇ ¿øÀÎÀÌ µÇ´Â ¿°Áõ °æ·Î¸¦ Â÷´ÜÇÔÀ¸·Î½á ÀÛ¿ëÇÏ¿© õ½Ä °ü¸®¿¡ È¿°úÀûÀÎ Àå±â Ä¡·áÁ¦·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. °øÇØ, ±âÈÄ º¯È­, »ýȰ½À°ü º¯È­·Î ÀÎÇÑ ¸¸¼º È£Èí±â ÁúȯÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Àü ¼¼°èÀûÀ¸·Î ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¸óÅ×·çÄ«½ºÆ®´Â ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å¿Í ´Þ¸® °æ±¸Åõ¿©°¡ °¡´ÉÇÏ°í ºÎÀÛ¿ëÀÌ ÀûÀ¸¸ç ¼Ò¾Æ¿¡°Ôµµ »ç¿ëÇÒ ¼ö ÀÖ¾î ¸¹Àº ȯÀÚµéÀÌ ¼±È£Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °èÀý¼º ¾Ë·¹¸£±â ¹× ´ë±â¿À¿°°ú °ü·ÃµÈ È£Èí±â Áúȯ Áõ°¡·Î ÀÎÇØ 󹿾à°ú ÀϹÝÀǾàǰ ¸ðµÎ ¸óÅ×·çÄ«½ºÆ®ÀÇ »ç¿ëÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀå ÀáÀç·ÂÀ» ³ôÀÌ´Â ÀǾàǰ Á¦ÇüÀÇ ¹ßÀüÀº ¹«¾ùÀΰ¡?

Á¦¾à¾÷°è¿¡¼­´Â ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ýÀÇ Á¦Çü°ú Àü´Þ¿¡ ÀÖ¾î Å« ÁøÀüÀÌ ÀÖ¾ú°í, »ýüÀÌ¿ë·ü°ú Ä¡·á È¿°ú°¡ Çâ»óµÇ¾ú½À´Ï´Ù. ¾Ã¾î¸ÔÀ» ¼ö ÀÖ´Â Á¤Á¦³ª °æ±¸¿ë °ú¸³ÀÇ °³¹ß·Î ¼Ò¾Æ ¹× ³ëÀΠȯÀÚµéÀÌ Ä¡·á ¿ä¹ýÀ» ½±°Ô ÁؼöÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ¸óÅ×·çÄ«½ºÆ®¿Í ·¹º¸¼¼Æ¼¸®Áø µîÀÇ Ç×È÷½ºÅ¸¹ÎÁ¦¿ÍÀÇ º´¿ë¿ä¹ýÀº ¾Ë·¹¸£±â Áõ»ó°ú È£Èí±â Áõ»ó ¸ðµÎ¿¡ È¿°ú°¡ ÀÖ¾î Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀ̰í Ä¡·á È¿°ú¸¦ Áö¼Ó½Ã۱â À§ÇØ ¹æÃâ Á¶Àý Á¦Á¦¸¦ Æ÷ÇÔÇÑ »õ·Î¿î ¾à¹° Àü´Þ ¸ÞÄ¿´ÏÁòµµ ¿¬±¸µÇ°í ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á·ÎÀÇ ÀüȯÀº ¸óÅ×·çÄ«½ºÆ®ÀÇ ¹ÝÀÀ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â À¯ÀüÀû ¿äÀο¡ ´ëÇÑ ¿¬±¸¸¦ ´õ¿í ÃËÁøÇÏ¿© º¸´Ù Ç¥ÀûÈ­µÇ°í È¿°úÀûÀÎ Ä¡·áÀÇ ±æÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù. Á¦¾àȸ»çµéÀÌ Çõ½ÅÀûÀÎ Á¦Çü¿¡ ´ëÇÑ ÅõÀÚ¸¦ Áö¼ÓÇÏ´Â °¡¿îµ¥, ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ýÀÇ Á¢±Ù¼º°ú »ç¿ë ÆíÀǼºÀÌ Çâ»óµÉ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

È£Èí±â ÁúȯÀÇ ºÎ´ã Áõ°¡´Â ½ÃÀå ¼ö¿ä¸¦ ¾î¶»°Ô Çü¼ºÇϰí Àִ°¡?

õ½Ä, ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), ¾Ë·¹¸£±â¼º ÁúȯÀÇ Àü ¼¼°è À¯º´·ü Áõ°¡·Î È¿°úÀûÀΠȣÈí±â Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϸ鼭 ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. µµ½ÃÈ­¿Í »ê¾÷È­´Â È£Èí±â ÁúȯÀÇ ÁÖ¿ä ¿øÀÎÀÎ ´ë±â¿À¿° Áõ°¡·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, È£Èí±â Áúȯ¿¡ Ãë¾àÇÑ ³ë·ÉÀα¸ Áõ°¡°¡ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÇ·áÁøÀº õ½Ä °ü¸®¸¦ °³¼±Çϱâ À§ÇØ ÈíÀÔ¿ë ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å¿Í ÇÔ²² ¸óÅ×·çÄ«½ºÆ®¸¦ º¸Á¶ ¿ä¹ýÀ¸·Î ±ÇÀåÇϰí ÀÖ½À´Ï´Ù. Äڷγª19 »çÅ´ ȣÈí±â °Ç°­¿¡ ´ëÇÑ °ü½ÉÀ» ³ôÀÌ°í ¸¸¼º È£Èí±â Áúȯ¿¡ ´ëÇÑ Àνİú Áø´ÜÀ²À» ³ôÀÌ´Â ¿ªÇÒµµ Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÈíÀÔÁ¦º¸´Ù ºñħ½ÀÀûÀÎ °æ±¸¿ë Ä¡·áÁ¦¸¦ ¼±È£Çϴ ȯÀÚµéÀÇ ¼±È£µµ°¡ ÀϺΠÁö¿ª¿¡¼­ ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ýÀ» 1Â÷ ¼±Åà ¾à¹°·Î äÅÃÇÏ´Â µ¥ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?

¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀåÀÇ ¼ºÀåÀº È£Èí±â ÁúȯÀÇ À¯º´·ü Áõ°¡, ÀǾàǰ Çõ½ÅÀÇ È®´ë, ¾Ë·¹¸£±â Áúȯ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ºñ¿ë È¿À²ÀûÀÌ°í ½±°Ô ±¸ÇÒ ¼ö Àִ õ½Ä Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä´Â ¼±Áø±¹°ú ½ÅÈï±¹ ½ÃÀå¿¡¼­ ¸óÅ×·çÄ«½ºÆ®ÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Á¦³×¸¯ ÀǾàǰ Á¦Á¶¾÷üÀÇ È®´ë´Â ½ÃÀå ħÅõ·ÂÀ» ³ô¿© ¸óÅ×·çÄ«½ºÆ®¸¦ º¸´Ù Àú·ÅÇÑ °¡°ÝÀ¸·Î ³Î¸® ÀÌ¿ëÇÒ ¼ö ÀÖµµ·Ï Çß½À´Ï´Ù. ¶ÇÇÑ, ¸óÅ×·çÄ«½ºÆ®¿Í Ç×È÷½ºÅ¸¹ÎÁ¦³ª ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵åÁ¦¿ÍÀÇ º´¿ë¿ä¹ýÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ Á¦¾à»çµé¿¡°Ô »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. õ½Ä °ü¸® ÇÁ·Î±×·¥À» ÃßÁøÇÏ·Á´Â Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê¿Í ½ÅÈï±¹ÀÇ ÀÇ·áºñ ÁöÃâ Áõ°¡´Â ½ÃÀå ¼ºÀå¿¡ ´õ¿í ±â¿©Çϰí ÀÖ½À´Ï´Ù. °³ÀÎ ¸ÂÃãÇü ÀÇ·á·ÎÀÇ Àüȯ°ú ´õ ³ªÀº Ä¡·á °á°ú¸¦ ¾ò±â À§ÇÑ ¹ÙÀÌ¿À¸¶Ä¿ ¿¬±¸µµ ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ýÀÇ ¹Ì·¡¸¦ ´õ¿í ¹à°ÔÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î È£Èí±â Áúȯ¿¡ ´ëÇÑ ºÎ´ãÀÌ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó ¸óÅ×·çÄ«½ºÆ® ³ªÆ®·ý ½ÃÀåÀº ÇâÈÄ ¸î ³â µ¿¾È Áö¼ÓÀûÀ¸·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

Á¦Çü(Á¤Á¦, °æ±¸Á¦);¿ëµµ(õ½Ä ¿ëµµ, ¾Ë·¹¸£±â¼º ºñ¿° ¿ëµµ, µÎµå·¯±â ¿ëµµ, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ¼­, ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Montelukast Sodium Market to Reach US$1.1 Billion by 2030

The global market for Montelukast Sodium estimated at US$504.7 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 14.1% over the analysis period 2024-2030. Tablets Form, one of the segments analyzed in the report, is expected to record a 12.5% CAGR and reach US$615.5 Million by the end of the analysis period. Growth in the Oral Solutions segment is estimated at 16.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$137.5 Million While China is Forecast to Grow at 18.6% CAGR

The Montelukast Sodium market in the U.S. is estimated at US$137.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$235.8 Million by the year 2030 trailing a CAGR of 18.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.6% and 12.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.2% CAGR.

Global Montelukast Sodium Market - Key Trends & Drivers Summarized

Why Is Montelukast Sodium Gaining Widespread Adoption in Respiratory Disease Treatment?

Montelukast sodium has become a widely prescribed pharmaceutical for managing respiratory conditions such as asthma, allergic rhinitis, and exercise-induced bronchoconstriction. As a leukotriene receptor antagonist (LTRA), montelukast works by blocking inflammatory pathways that contribute to airway constriction, making it an effective long-term therapy for asthma management. With the increasing prevalence of chronic respiratory diseases due to pollution, climate change, and lifestyle factors, the demand for montelukast sodium has surged globally. Unlike corticosteroids, montelukast is preferred by many patients due to its oral administration, fewer side effects, and suitability for pediatric use. Additionally, the rise in seasonal allergies and air pollution-related respiratory issues has expanded the use of montelukast in both prescription and over-the-counter formulations.

What Advancements in Pharmaceutical Formulations Are Enhancing Montelukast Sodium's Market Potential?

The pharmaceutical industry has witnessed significant advancements in the formulation and delivery of montelukast sodium, improving its bioavailability and therapeutic efficacy. The development of chewable tablets and oral granules has made it easier for pediatric and geriatric patients to adhere to treatment regimens. Additionally, combination therapies incorporating montelukast with antihistamines, such as levocetirizine, have gained popularity for their dual-action benefits in managing both allergic and respiratory symptoms. Novel drug delivery mechanisms, including controlled-release formulations, are also being explored to improve patient compliance and prolong therapeutic effects. The shift toward personalized medicine has further driven research into genetic factors influencing montelukast response, paving the way for more targeted and effective treatments. As pharmaceutical companies continue to invest in innovative drug formulations, the accessibility and usability of montelukast sodium are expected to improve.

How Is the Rising Burden of Respiratory Diseases Shaping Market Demand?

The increasing global incidence of asthma, chronic obstructive pulmonary disease (COPD), and allergic conditions has created a substantial demand for effective respiratory therapies, boosting the montelukast sodium market. Urbanization and industrialization have led to rising levels of air pollution, a key trigger for respiratory conditions. Additionally, the growing geriatric population, which is more prone to respiratory diseases, has contributed to market expansion. Healthcare providers are increasingly recommending montelukast as an adjunct therapy alongside inhaled corticosteroids for better asthma management. The COVID-19 pandemic has also played a role in shifting attention toward respiratory health, increasing awareness and diagnosis rates for chronic respiratory conditions. Furthermore, patient preference for non-invasive, oral treatments over inhaled medications has bolstered the adoption of montelukast sodium as a first-line therapy in several regions.

What Are the Key Factors Driving Growth in the Montelukast Sodium Market?

The growth in the montelukast sodium market is driven by several factors, including the rising prevalence of respiratory diseases, expanding pharmaceutical innovations, and increasing awareness about allergic conditions. The demand for cost-effective and easily accessible asthma treatments has propelled the adoption of montelukast across developed and emerging markets. The expansion of generic drug manufacturers has also increased market penetration, making montelukast more affordable and widely available. Additionally, the growing use of combination therapies, where montelukast is paired with antihistamines or corticosteroids, is creating new opportunities for pharmaceutical companies. Government initiatives promoting asthma management programs and increased healthcare spending in emerging economies are further contributing to market growth. The shift toward personalized medicine and research into biomarkers for better treatment outcomes is also expected to enhance the future potential of montelukast sodium. As the global burden of respiratory diseases continues to rise, the montelukast sodium market is set for sustained expansion in the coming years.

SCOPE OF STUDY:

The report analyzes the Montelukast Sodium market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Dosage Form (Tablets Form, Oral Solutions); Application (Asthma Application, Allergic Rhinitis Application, Urticaria Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â